Effect on short- and long-term major adverse cardiac events of statin treatment in patients with acute myocardial infarction and renal dysfunction
The American Journal of Cardiology,  Clinical Article

Lim SY et al. – Statin therapy reduced major adverse cardiac events (MACE) at 1 year of follow–up in patients with acute myocardial infarction (AMI) regardless of renal dysfunction (RD).

Methods
  • The 3–hydroxy–3–methylglutaryl–coenzyme A reductase inhibitors (statins) reduce major adverse cardiac events (MACE) and mortality in patients with acute coronary syndrome.
  • Authors investigated the effectiveness of statin therapy in reducing MACE in patients with acute myocardial infarction (AMI) and renal dysfunction (RD).
  • In the present retrospective study of 12,853 patients with AMI, the patients were categorized into 4 groups: group I, statin therapy and no RD (estimated glomerular filtration rate ≥60 ml/min/1.73 m2); group II, neither statin therapy nor RD; group III, statin therapy and RD; group IV, no statin therapy but RD.
  • The primary end points were death and complications during the hospital course.
  • The secondary end points were MACE during 1 year of follow–up after AMI.

Results
  • Significant differences in the composite MACE during 12 months of follow–up were observed among the 4 groups (group I, 11.7%; group II, 19.0%; group III, 26.7%; and group IV, 45.5%; p <0.001).
  • In a Cox proportional hazards model, mortality at 12 months increased stepwise from group II to IV compared to group I.
  • Moreover, MACE–free survival in the severe RD group (estimated glomerular filtration rate <30 mL/min/1.73 m2) was also greater in the statin–treated group.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Cardiology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

<

Most Popular Cardiology Articles

1 New test to measure HDL cholesterol can predict cardiovascular risk Medical University of Vienna, December 1, 2014

2 Study shows epinephrine may do more harm than good in cardiac arrest American College of Cardiology News, December 5, 2014

3 Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials Hypertension, September 29, 2014    Evidence Based Medicine    Review Article

4 Effects of tea intake on blood pressure: A meta-analysis of 21 randomized controlled trials JACC - Journal of the American College of Cardiology, October 22, 2014    Clinical Article

5 Cans lined with Bisphenol A may increase blood pressure American Heart Association News, December 10, 2014

6 Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT Journal of the American Society of Hypertension, November 4, 2014    Clinical Article

7 Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study The Lancet, December 3, 2014    Evidence Based Medicine    Clinical Article

8 A systematic review of aspirin in primary prevention: Is it time for a new approach? American Journal of Cardiovascular Drugs, December 12, 2014    Evidence Based Medicine    Review Article

9 Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial The Lancet, December 1, 2014    Clinical Article

10 Catheter ablation versus anti-arrhythmic drug therapy for the management of a trial fibrillation: a meta-analysis Journal of Interventional Cardiac Electrophysiology , December 15, 2014    Clinical Article

11 Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: A randomized, placebo-controlled trial Full Text Nutrition Journal, November 15, 2013    Free full text    Clinical Article

12 Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation European Heart Journal, September 16, 2014    Clinical Article

13 Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial JAMA, December 22, 2014    Evidence Based Medicine    Clinical Article

14 Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation International Journal of Cardiology, November 26, 2014    Clinical Article

15 Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy EP Europace, September 19, 2014    Clinical Article

16 Perioperative beta blockade in noncardiac surgery: A systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery Circulation, December 23, 2014    Evidence Based Medicine    Review Article

17 Speedy heart transplant for kids better than waiting for perfect match American Heart Association News, November 24, 2014

18 What the guidelines do not say: statin non-benefit groups Current Atherosclerosis Reports, November 20, 2014    Clinical Guideline    Clinical Article

19 Mechanical versus manual chest compression for out-of-hospital cardiac arrest (PARAMEDIC): a pragmatic, cluster randomised controlled trial The Lancet, December 1, 2014    Evidence Based Medicine    Clinical Article

20 Exercise-based cardiac rehabilitation in patients with heart failure: A meta-analysis of randomised controlled trials between 1999 and 2013 European Journal of Preventive Cardiology, November 21, 2014    Evidence Based Medicine    Review Article    Clinical Article

Indexed Journals in Cardiology: American Heart Journal, American Journal of Cardiology, Circulationn, Heartmore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List